Head-to-head evidence
Cariprazine (Vraylar) vs JX11502MA
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D3/D2 receptor (partial agonist) · full Schizophrenia pipeline
Cariprazine (Vraylar)
Marketed by AbbVie and partners
NCT01104766 · Phase 3 · completed
The trial randomized 617 participants to cariprazine 3 mg, cariprazine 6 mg, aripiprazole 10 mg, or placebo, with participants, investigators, and outcome assessors masked. The prespecified clinical primary endpoint, change in PANSS total score at week 6, was significantly improved with both cariprazine doses versus placebo (p=0.0044 and p<0.0001), supporting a strong evidence grade.
Next expected readout: December 2026 · NCT03817502 (registry estimate)
JX11502MA
Developed by Zhejiang Jingxin Pharmaceutical Co., Ltd.
NCT06356389 · Phase 1/2 · completed
The study randomized 60 participants to JX11502MA or placebo and used double blinding, but the registry does not report whether the primary safety endpoint was met. Because the results are unavailable, the evidence supports only a limited assessment rather than a definitive conclusion.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cariprazine (Vraylar)'s landscape · JX11502MA's landscape